Home

September 2019 All Member CallBedaquiline AccessNTCA Provider Guidance on Using the Isoniazid/Rifapentine Regimen to Treat Latent Tuberculosis Infection (LTBI)Save the Date for the 2020 National TB Conference

About the National Tuberculosis Controllers Association

The NTCA was created in 1995 to bring together the leaders of tuberculosis control programs in all states and territories, as well as many counties and city health departments that organize their own TB control activities. Learn more…

  • Home page noteworthy

    Noteworthy

    APLISOL® Inventory Replenished

    August 26 — FDA has removed APLISOL® from its current shortage listing. APLISOL® is now listed on the CBER-Regulated Products: Resolved Shortages webpage. In response to a call from NTCA, the manufacturer of APLISOL®, Par Pharmaceutical Companies Inc., stated that all geographic markets/wholesalers throughout the US should have adequate inventory now. In another call, Sanofi confirmed that Tubersol® is still in allocation and that the company still anticipated an 8/31 assessment date to know if allocation would continue. Programs are encouraged to let NTCA know if you are having challenges procuring either PPD solution.

    Updated Recommendations Released for Health Care Personnel

    May 16 — NTCA, in partnership with the CDC, is pleased to announce the release of updated recommendations for TB screening, testing, and treatment of health care personnel. Central to the new recommendations is stopping routine, annual testing of all health care personnel and the emphasis on LTBI treatment, an essential component of national efforts to eliminate TB. We extend our thanks to Lynn Sosa and Bob Belknap, who led the national workgroup, and to the committed stakeholders from NTCA and our partner organizations. For more, see the NTCA press release and the updated recommendations.